Data room › Section 6 of 8
The round
The terms below are directed only at investors who qualify as certified high net worth individuals or self-certified sophisticated investors. Please confirm before continuing.
Mavis is raising £500,000
Confirm your investor status
Capital at risk. Investing in early-stage businesses involves risks including loss of capital, illiquidity and dilution. You should not invest more than you can afford to lose, and you should seek independent advice.
This page has not been approved by a person authorised under the Financial Services and Markets Act 2000. It is directed only at people who fall within the exemptions for certified high net worth individuals and self-certified sophisticated investors.
Terms
| Round | Seed 2026 |
| Raising | £500,000 |
| Pre-money valuation | £2M |
| Equity offered | 20.0% |
| Price per share | £8.2260 |
| Minimum investment | £10,000 |
| Committed so far | £0 (0%) |
| Instrument | Ordinary shares |
| EIS | Eligible for UK investors, subject to HMRC and your own circumstances |
| Previous round | Pre-Seed 2025 — complete at £1.65M pre-money |
Use of funds
What it funds
This round covers the remaining cash trough of roughly £399,000 with around £100,000 of headroom, and takes Mavis to EBITDA-positive trading in 2028 and cash-flow-positive trading in 2029. The 2026 position is already funded by the first round, grants and R&D tax relief. No further capital is required to reach profitability; a modelled £2M Series A in 2029 funds international expansion.
Forecast and returns
The six-year model forecasts £22.4M revenue and £6.5M EBITDA in 2031 on 14,000 units and 21,769 subscribers. At an exit multiple of 9–15× EBITDA that is a £59–98M exit and a 19–31× return to this round, stated after dilution from the modelled Series A, which takes this round from 20% to 16%. Most likely route is a strategic acquisition by a healthcare-technology or medical-device company in five to seven years. These are forecasts, not guarantees.
How to invest
Register as an investor and David will approve your access, usually within a working day. In the investor portal you can download the financial model and documents, then request the amount you have in mind. You will receive the term sheet, share subscription agreement and deed of adherence to sign electronically, then a share certificate once funds are received and the shares are allotted. Existing shareholders can request to invest and follow their investment in the same portal.
| Round | Pre-money | Price per share | Raised | Investors | |
|---|---|---|---|---|---|
| Seed 2026 Open | £2M | £8.2260 | £50,000 of £500,000 (10%) | 1 | 20.0% |
| Pre-Seed 2025 Closed | £1.65M | — | £259,872 | — | £1.91M post-money |
Figures come live from the company's share register. Investor names and individual amounts are never published; shareholders can see their own holding in the investor portal.